Mr. Cable counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters. He represents buyers, sellers and investment banks in his M&A practice, as well as the private equity and venture sources investing in such companies and investment banks serving such industries.
During his distinguished career, Mr. Cable has played a central role in executing more than 400 M&A transactions, with a particular focus on the technology and life sciences industries. In addition to his M&A work, Mr. Cable regularly represents issuers and underwriters in a myriad of capital market offerings.
Mr. Cable’s representative clients include, among others: AMAG, Ansys, AvroBio, Aura, Cerevel, Citrix, Corbus, Flagship Pioneering, Mirati, Moderna, MyoKardia, Ohana, PAREXEL, PTC, Repertoire Immune Medicines, Plug Power, Rubius, Shields Healthcare Solutions, Spark, Valo Health, and Yumanity.
Representative Transactions
His recent and notable representations include:
- Financial advisor in connection with Pandion Therapeutics’ 2021 definitive sale to Merck ($1.85 billion)
- The Special Committee of the Board of Directors of NantKwest in NantKwest’s merger with ImmunityBio
- MyoKardia in its 2020 acquisition by Bristol Myers Squibb ($13.1 billion)
- AMAG Pharmaceuticals in its 2020 sale to Covis Group ($500 million)
- Macquarie Capital and GCM Grosvenor in connection with their 2020 agreement to acquire Alaska Communications Systems Group ($500 million)
- Cerevel Therapeutics in its business combination with ARYA Sciences Acquisition Corp II ($440 million)
- Financial advisor in connection with Immunomedics’ 2020 sale to Gilead Sciences, Inc. ($20 billion)
- Moderna in its 2020 follow-on public offerings ($500 million in March and $1.34 billion in May)
- The Transaction Committee of Sprint in connection with Sprint Corporation’s 2020 merger with T-Mobile US, Inc. ($26 billion)
- Financial advisor in connection with Principia Biopharma’s 2020 acquisition by Sanofi ($3.68 billion)
- Financial advisor in connection with Forty Seven’s 2020 acquisition by Gilead Sciences ($4.9 billion)
- Spark Therapeutics in its 2019 sale to Roche ($4.4 billion)
- Financial advisor in connection with Arqule’s 2020 acquisition by Merck ($2.7 billion)
- Civitas in its 2019 acquisition by Centerbridge ($1.4 billion)
- Moderna in its 2018 record initial public offering ($604 million)
- Keryx in its 2018 merger with Akebia ($1.3 billion)
- PTC in its 2018 strategic partnership with Rockwell Automation ($1 billion)
- Foundation Medicine in its 2015 majority sale to Roche ($1 billion) and the subsequent 2018 negotiated tender for the public stub by Roche ($2.4 billion)
- The private company acquisition and subsequent 2018 sale of Cord Blood Registry by AMAG Pharmaceuticals
- The abandoned 2018 acquisition of NXP by Qualcomm ($47 billion)
- inviCRO in its 2017 sale to Konica Minolta (Japan) ($300 million)
- PAREXEL in its 2017 sale to Pamplona ($5 billion)
- AMRI in its 2017 sale to Carlyle and GTCR ($1.9 billion)
- Teva Pharmaceuticals in its 2015 acquisition of Auspex ($3.5 billion)
- Financial advisor in connection with Pharmacyclics’ 2015 sale to AbbVie ($21 billion)
- AMRI in its 2016 and 2015 cross border private company acquisitions of Euticals ($358 million – Italy) and Gadea ($174 million – Spain)
- The private company sale of Stemcentrix to Abbvie ($5.8 billion)
- The 2016 Reverse Morris Trust merger of a division of Citrix into LogMeIn ($2 billion)
- Xoom in its 2015 sale to PayPal ($1 billion)
- Onyx Pharmaceuticals in its 2013 sale to Amgen ($10.4 billion)
- Eloqua in its 2012 sale to Oracle ($1 billion)
Mr. Cable is also retained from time to time to represent "independent" or "special" committees of the Board of Directors in complex M&A transactions, including most recently the representation of the Special Committee of the Board of Directors of NantKwest in NantKwest’s merger with ImmunityBio and the Transaction Committee of Sprint in Sprint Corporation’s merger with T-Mobile US, Inc.
